plitidepsin + dexamethasone

Plitidepsin + dexamethasone is a combination regimen indicated for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens including both a proteasome inhibitor and an immunomodulator[2][4][5]. Plitidepsin is a synthetically manufactured cyclic depsipeptide that targets elongation factor 1 alpha 2 (eEF1A2), a protein overexpressed in multiple myeloma cells, leading to inhibition of protein synthesis and induction of apoptosis[7]. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and antineoplastic activity, widely used in multiple myeloma regimens for its cytotoxic and immunosuppressive effects. Plitidepsin + dexamethasone has demonstrated improved progression-free survival compared to dexamethasone alone in clinical trials but is associated with increased toxicity, including nausea, vomiting, diarrhoea, myalgia, liver enzyme elevations, fatigue, and increased risk of atrial fibrillation[1][2][4][5]. The combination is approved for clinical use in Australia, but has not received marketing authorization in the European Union[2][4][8].

Other names

plitidepsin and dexamethasoneplitidepsin+dexamethasone